188 related articles for article (PubMed ID: 37903311)
21. Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML).
Ghiraldeli L; Anderson R; Pladna K; Pardee TS
Cancer Lett; 2022 Jun; 535():215659. PubMed ID: 35321842
[TBL] [Abstract][Full Text] [Related]
22. Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
Root JL; Desai PN; Ly C; Wang B; Jelloul FZ; Zhou J; Mackay S; Alfayez M; Matthews J; Pierce S; Reville PK; Daver N; Abbas HA
Cancer Res Commun; 2024 Mar; 4(3):671-681. PubMed ID: 38391202
[TBL] [Abstract][Full Text] [Related]
23. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
24. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice.
Pawlowska AB; Hashino S; McKenna H; Weigel BJ; Taylor PA; Blazar BR
Blood; 2001 Mar; 97(5):1474-82. PubMed ID: 11222396
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
26. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
27. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT.
Wang D; Sun Z; Zhu X; Zheng X; Zhou Y; Lu Y; Yan P; Wang H; Liu H; Jin J; Zhu H; Sun R; Wang Y; Fu B; Tian Z; Wei H
Blood; 2022 Dec; 140(26):2788-2804. PubMed ID: 35981475
[TBL] [Abstract][Full Text] [Related]
28. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.
Fucikova J; Truxova I; Hensler M; Becht E; Kasikova L; Moserova I; Vosahlikova S; Klouckova J; Church SE; Cremer I; Kepp O; Kroemer G; Galluzzi L; Salek C; Spisek R
Blood; 2016 Dec; 128(26):3113-3124. PubMed ID: 27802968
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in Myeloproliferative Diseases.
Braun LM; Zeiser R
Cells; 2020 Jun; 9(6):. PubMed ID: 32604862
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
32. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
Yang T; Chen ZZ; Kolb HJ; Buhmann R
Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
34. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
35. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!
Haddad F; Daver N
Adv Exp Med Biol; 2021; 1342():273-295. PubMed ID: 34972969
[TBL] [Abstract][Full Text] [Related]
36. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
37. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
[TBL] [Abstract][Full Text] [Related]
38. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
39. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia.
Zhong RK; Rassenti LZ; Kipps TJ; Chen J; Law P; Yu JF; Ball ED
Biol Blood Marrow Transplant; 2002; 8(10):557-68. PubMed ID: 12434951
[TBL] [Abstract][Full Text] [Related]
40. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
